Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.13429
Abstract: A single‐dose, shield‐activated pen‐injector for each of the three approved dose variants (0.25, 0.5 and 1 mg) of once‐weekly subcutaneous semaglutide has been developed to improve usability. This analysis presents findings from the summative usability… read more here.
Keywords: usability testing; evaluating usability; pen injectors; single dose ... See more keywords